Trials / Completed
CompletedNCT04208386
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989
A Phase 1, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of JNJ-73763989
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Janssen Sciences Ireland UC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the single-dose pharmacokinetic (PK) of JNJ-73763976 and JNJ-73763924 following a subcutaneous (SC) injection of JNJ-73763989 (JNJ-3989) in participants with liver cirrhosis and various degrees of impaired hepatic function when compared with healthy participants with normal hepatic function and no liver cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-73763989 | JNJ-73763989 will be administered SC under fasted condition. |
Timeline
- Start date
- 2020-01-08
- Primary completion
- 2020-07-20
- Completion
- 2020-07-20
- First posted
- 2019-12-23
- Last updated
- 2020-09-30
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04208386. Inclusion in this directory is not an endorsement.